clobetasol profile

Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5311051
CHEMBL ID	1201362
CHEBI ID	205919
SCHEMBL ID	3996
MeSH ID	M0004578

Synonym
AC-1775
clobecort amex (tn)
25122-41-2
D07715
clobetasol (inn)
clobetasol
einecs 246-633-8
clobetasolum [inn-latin]
clofenazon
clobetasol [inn:ban]
pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-
CHEMBL1201362
(8s,9r,10s,11s,13s,14s,16s,17r)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
clobecort amex
dovate
21-chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
clobetasolum
(11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
chebi:205919 ,
cas-25122-41-2
dtxsid2048955 ,
dtxcid9028881
tox21_113384
adn79d536h ,
unii-adn79d536h
hsdb 7994
clobetasol impurity g (pheur)
clobetasol [mi]
betamethasone impurity b [ep impurity]
clobetasol [vandf]
clobetasol [who-dd]
pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.beta.)-
clobetasol [inn]
clobetasol propionate impurity g [ep impurity]
SCHEMBL3996
AKOS025401451
(1r,2s,10s,11s,13s,14r,15s,17s)-14-(2-chloroacetyl)-1-fluoro-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
clobetasol, >=95.0% (hplc), pharmaceutical impurity standard
21-chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione (clobetasol)
J-015820
DB11750
Q4224007
furfurylacrylate
CS-0450071
(1r,2s,3as,3bs,9as,9br,10s,11as)-1-(2-chloroacetyl)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
EN300-19844878
clobetasolum (inn-latin)
clobetasolo
d07ad01
betamethasone impurity b (ep impurity)

Excerpt	Reference	Relevance
"Clobetasol is an effective treatment for abutment skin/scar overgrowth. "	( Bone-anchored hearing aid abutment skin overgrowth reduction with clobetasol. Falcone, MT; Haynes, DS; Kaylie, DM; Labadie, RF, 2008)	2.03
"Clobetasol propionate is a super-high potent class 1 topical corticosteroid available in several formulations, including a spray formulation that is approved for use up to 4 weeks in patients aged 18 years and older with moderate to severe plaque psoriasis. "	( Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. Menter, A, 2012)	3.26
"Clobetasol propionate is a super-highpotent class I topical corticosteroid."	( Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis. Caveney, SW; Gottschalk, RW; Menter, MA, 2012)	1.5
"Clobetasol propionate is a very effective treatment for psoriasis. "	( Clobetasol propionate for psoriasis: are ointments really more potent? Balkrishnan, R; Feldman, SR; Warino, L, 2006)	3.22
"Clobetasol mouthwash is a safe and efficacious option for the treatment of severe oral erosive lesions."	( Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Gonzalez-Moles, MA; Gonzalez-Moles, S; Isabel, IR; Morales, P; Rodriguez-Archilla, A, 2002)	2.01

Excerpt	Reference	Relevance
"Clobetasol has significantly higher efficacy and tacrolimus may be an alternative treatment."	( A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Janjumratsang, P; Pothinamthong, P, 2012)	1.33

Excerpt	Reference	Relevance
"Clobetasol proved to inhibit UVB-induced proliferation of epidermal cells, tenascin induction, keratin 16 induction and the accumulation of T lymphocytes and CD1a-positive cells."	( Effects of calcipotriol and clobetasol-17-propionate on UVB-irradiated human skin: an immunohistochemical study. de Jong, EM; Snijders, CG; van de Kerkhof, PC; van der Vleuten, CJ, 1996)	1.31

Excerpt	Reference	Relevance
"Clobetasol treatment ranked as the best treatment for disease remission after evaluating rank probabilities (40% chance of ranking first compared with tacrolimus [38%])."	( An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets. Bellos, I; Biliou, EC; Doumouchtsis, SK; Mitsopoulou, D; Pergialiotis, V; Varnava, P, 2020)	1.28
"Clobetasol treatment exhibited an equivalent pharmacological effect."	( Clobetasol Modulates Adult Neural Stem Cell Growth via Canonical Hedgehog Pathway Activation. Bernstock, JD; Giallongo, C; Giunta, MAS; Gulino, R; Gulisano, M; Leanza, G; Li Volti, G; Parenti, R; Spitale, FM; Tibullo, D; Vicario, N, 2019)	2.68
"Clobetasol treatment of U937 cells induced an up- and down-regulation of SLPI expression in a dose-dependent manner."	( Clobetasol down-regulates SLPI expression in U937 monocytoid cells. Kitagishi, Y; Matsuda, S; Nishimura, Y; Okumura, N; Yoshida, H, 2012)	2.54
"Treatment with clobetasol ointment was successful without necessitating discontinuation of immunotherapy."	( PD1 inhibitor induced inverse lichenoid eruption: a case series. Garg, V; Lee, JB; Sethi, M; Yang, S, 2020)	0.9
"Treatment with clobetasol propionate 0.05% spray for up to four weeks is effective and well tolerated for moderate-to-severe plaque psoriasis of the scalp."	( Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. Caveney, SW; Colón, LE; Cook-Bolden, FE; Gottschalk, RW; Hudson, CP; Preston, N; Sofen, H, 2011)	2.16
"Treatment with clobetasol cream 0.05% led to resolution of his lichen planus lesions."	( Imiquimod reactivation of lichen planus. Chaney, KC; Domingues, E; Scharf, MJ; Wiss, K, 2012)	0.72
"Pretreatment with clobetasol-17-propionate, applied three times a day for 4 days, did not affect the activity of galactosylhydroxylysyl glucosyltransferase (GGT) in fresh blisters but post-blistering treatment for 3 days with the steroid markedly inhibited the increase of this enzyme activity during the initial phases of re-epithelialization."	( A local potent glucocorticosteroid decreases the induction of galactosylhydroxylysyl glucosyltransferase in suction blisters but has no effect on basement membrane structures. Foidart, JM; Hintikka, J; Kiistala, U; Oikarinen, A; Peltonen, L, 1983)	0.59
"Treatment with clobetasol kept patients free from relapses during the entire observation period in 70%, with flupredniden in 30%."	( Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and flupredniden acetate. Dahl, G; Möller, H; Svartholm, H, 1983)	0.85
"Treatment with clobetasol propionate 0.05% cream is effective against lichen sclerosus et atrophicus (LSA) of the vulva."	( Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. Dahlman-Ghozlan, K; Hedblad, MA; von Krogh, G, 1999)	0.91
"Pretreatment with clobetasole-17-propionate cream on the skin for 1 week prior to prick tests did not affect the blood flow response elicited by histamine or allergen, in either the initial part (up to 1 h) or the protracted 24 h determinations."	( Blood flow in histamine- and allergen-induced weal and flare responses, effects of an H1 antagonist, alpha-adrenoceptor agonist and a topical glucocorticoid. Hammarlund, A; Olsson, P; Pipkorn, U, 1990)	0.6

Excerpt	Reference	Relevance
" No other adverse cutaneous effects were observed."	( The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Freer, JP; Kalb, RE; Krochmal, L; Siskin, SB; Watson, WA, 1990)	0.28
" From the above evidence, it was concluded that HBP ointment was less toxic than the other topical corticosteroids."	( Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats. Kimura, M; Nakane, S; Otomo, S; Tarumoto, Y, 1986)	0.27
"3 mg/kg/day, however, some dose-dependent symptoms such as suppression of body weight gain, emaciation, regressive changes in adrenals, lymphatic and hematopoietic tissues, decrease in circulating white blood cell and lymphocyte counts, which have been known as toxic effects of synthetic corticosteroids, were induced."	( [Studies on toxicity of clobetasone-17-butyrate (II)--chronic toxicity in rats (author's transl)]. Aoishi, M; Bando, T; Ezaki, H; Hashimoto, K; Matsumoto, M; Moriwaki, T; Nagasawa, R; Okamura, C; Sato, N; Sutoh, M; Tamura, J; Tatami, A, 1980)	0.26
" Adverse events were reported by 34."	( Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Bressinck, R; Cornell, R; Katz, HI; Lindholm, JS; Morman, M; Pariser, DM; Pariser, RJ; Shavin, JS; Weiss, JS; Weng, W, )	0.35
" Despite earlier fears, widespread availability and use of these creams is not associated with clinically significant adverse effects."	( Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety. Cork, MJ; Goustas, P; Higson, D, 2003)	0.32
" Adverse events were more common in the calcipotriol group than in the clobetasol propionate shampoo group."	( Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Acebes, LO; Arsonnaud, S; Caputo, R; de Waard-van der Spek, FB; Decroix, J; Figueiredo, A; Mrowietz, U; Poncet, M; Reygagne, P, 2005)	2
" Clobetasol propionate lotion was safe and well tolerated."	( Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. Feldman, SR; Foley, V; Lin, YL; Lowe, N; Shavin, JS; Sherer, D; Soto, P; Weiss, J, 2005)	2.68
"The present study demonstrates that clobetasol propionate lotion is an efficacious, safe and well-tolerated alternative to the currently available emollient cream formulation, while showing a better remission profile after 4 weeks of treatment-free follow-up period."	( Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. Feldman, SR; Foley, V; Lin, YL; Lowe, N; Shavin, JS; Sherer, D; Soto, P; Weiss, J, 2005)	2.05
" No adverse events were recorded during the trial in either treatment group."	( Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial. Cassano, N; D'Argento, V; Milani, M; Vena, GA, 2006)	1.78
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Adverse events were reported throughout the study."	( An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Beutner, K; Chakrabarty, A; Lemke, S; Yu, K, 2006)	0.57
" No serious adverse event occurred during the course of the study."	( An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Beutner, K; Chakrabarty, A; Lemke, S; Yu, K, 2006)	0.57
"05% spray was effective and safe in reducing overall plaque severity, scaling, erythema, and plaque elevation from the first week of treatment continuing throughout the trial."	( An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Beutner, K; Chakrabarty, A; Lemke, S; Yu, K, 2006)	0.57
" Both treatments were safe and well-tolerated."	( A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Arsonnaud, S; Barker, JN; Finlay, AY; Fleming, CJ; Griffiths, CE; Mizzi, F, 2006)	0.56
"This new formulation of clobetasol propionate foam is an effective, safe and well-tolerated topical treatment for AA."	( Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. Botta, GL; Iorizzo, M; Milani, M; Tosti, A, 2006)	0.93
" No treatment-related serious adverse events occurred during the course of the study."	( Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Brodell, RT; Clark, SD; Jarratt, MT; Safley, CF; Savin, RC; Swinyer, LJ; Yu, K, 2006)	0.6
"While glucocorticoids (GC) exert beneficial effects (anti-inflammatory), they also have adverse effects on the epidermis including decreased epidermal differentiation, decreased keratinocyte proliferation, and decreased cutaneous permeability barrier homeostasis."	( Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Chang, S; Choi, EH; Demerjian, M; Elias, PM; Feingold, KR; Man, MQ, 2009)	0.35
" CP shampoo was also safe during the 7-month study period, without leading to more cases of skin atrophy, telangiectasia, hypothalamic-pituitary-adrenal (HPA) axis suppression or adverse events compared to vehicle."	( Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. Barber, K; Bissonnette, R; Kerrouche, N; Papp, K; Poulin, Y; Villemagne, H, 2010)	1.8
"05% is an efficacious and safe treatment for scalp psoriasis."	( Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Bissonnette, R; Guenther, L; Kerrouche, N; Lynde, C; Papp, K; Poulin, Y; Tan, J; Villemagne, H, 2010)	1.8
" Topical vitamin D, which is used to treat mild-to-moderate psoriasis, has been shown to be safe when used daily for up to 52 weeks."	( A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis. Brodell, RT; Bruce, S; Colón, LE; Gottschalk, RW; Hudson, CP; Johnson, LA; Weiss, JS, 2011)	0.58
" The sequential treatment regimen was well tolerated with no unexpected adverse events."	( A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis. Brodell, RT; Bruce, S; Colón, LE; Gottschalk, RW; Hudson, CP; Johnson, LA; Weiss, JS, 2011)	0.58
"05% spray treatment for four weeks immediately followed by an eight-week treatment phase with calcitriol 3 μg/g ointment is efficacious and safe for the management of moderate-to-severe plaque psoriasis."	( A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis. Brodell, RT; Bruce, S; Colón, LE; Gottschalk, RW; Hudson, CP; Johnson, LA; Weiss, JS, 2011)	0.58
" The short-contact clobetasol propionate 0·05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis."	( Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Faergemann, J; Kerrouche, N; Lee, JH; Nikkels, AF; Ortonne, JP; Ponce Olivera, RM; Reich, K; Sidou, F, 2011)	0.92
" Similarly low incidences of telangiectasia, burning and adverse events were observed among the four groups."	( Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Faergemann, J; Kerrouche, N; Lee, JH; Nikkels, AF; Ortonne, JP; Ponce Olivera, RM; Reich, K; Sidou, F, 2011)	0.59
" Dermatologists seek alternative treatments of patients with plaque psoriasis that provide both efficacy and safety while minimizing exposure to high-potency steroids that can have adverse effects following long-term use."	( An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Colón, LE; Gottschalk, R; Hudson, CP; Johnson, LA; Kempers, S; Menter, A; Papp, K; Smith, S; Sofen, H, 2011)	0.59
" Although highly effective, long-term use of topical steroids can cause adverse side effects."	( An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Colón, LE; Gottschalk, R; Hudson, CP; Johnson, LA; Kempers, S; Menter, A; Papp, K; Smith, S; Sofen, H, 2011)	0.57
" Clobetasone butyrate, at low dosage, proved to be safe and effective in treating this condition."	( Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Aragona, P; Postorino, E; Puzzolo, D; Rania, L; Roszkowska, AM; Sommario, MS; Spinella, R, )	0.13
" Adverse events (AEs) were reported in 18% of subjects in the clobetasol propionate foam group and 8% of subjects in the vehicle foam group."	( A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis. Eastman, WJ; Gwazdauskas, J; Kircik, LH, 2013)	0.85
" Comparable numbers of adverse events occurred in each arm."	( A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Callis Duffin, K; Hooper, M; Kircik, L; Koo, J; Kricorian, G; Lebwohl, MG; Pariser, D; Thompson, EH; Wenkert, D; Yang, J, 2013)	0.39
"Addition of CP to etanercept yielded increased efficacy compared with etanercept alone at week 12 without an increase in treatment-related adverse events."	( A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Callis Duffin, K; Hooper, M; Kircik, L; Koo, J; Kricorian, G; Lebwohl, MG; Pariser, D; Thompson, EH; Wenkert, D; Yang, J, 2013)	0.39
" For many inflammatory-based scalp diseases, glucocorticoids are an essential part of treatment, even though they are known to cause systemic as well as local adverse effects when applied topically."	( Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. Beck, RCR; Conrad, P; De Rossi, C; Garrigues, TM; Guterres, SS; Hansen, S; Lehr, CM; Mathes, C; Melero, A; Pohlmann, AR; Prado, WA; Rigo, L; Schaefer, UF; Selzer, D; Vogt, T, 2016)	0.64
" Safety and treatment emergent adverse events (TEAEs) were evaluated throughout."	( A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL, 2017)	0.46
" The adverse effects (most commonly hyperpigmentation) were noted more frequently on the excimer-treated sides; however, they were well tolerated."	( Comparison of effectiveness and safety of excimer lamp vs topical calcipotriol-clobetasol propionate combination in the treatment of palmoplantar psoriasis. Bishnoi, A; Dogra, S; Narang, T; Thakur, A, 2018)	0.71
" Safety and treatment-emergent adverse events were evaluated throughout."	( Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018)	0.48
" The most frequently reported treatment-related adverse events were contact dermatitis (6."	( Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018)	0.48
" The target Nail Psoriasis Severity Index (NAPSI) score of each finger was evaluated, any adverse effects were recorded, and photographs were taken."	( A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails. Boontaveeyuwat, E; Danchaivijitr, N; Silpa-Archa, N; Wongpraparut, C, 2019)	0.73
"In spite of its temporary effect, the intralesional triamcinolone injection is an effective and safe treatment for psoriatic nails."	( A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails. Boontaveeyuwat, E; Danchaivijitr, N; Silpa-Archa, N; Wongpraparut, C, 2019)	0.73
" Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs)."	( A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Geskin, L; Lopez, AT, 2018)	0.48
"PD-1/PD-L1 inhibitor-induced bullous pemphigoid (BP) is a rare but potentially serious dermatologic toxicity associated with checkpoint inhibitorsIn patients with pruritus or rash that is refractory to topical steroids, physicians should have a greater index of suspicion for higher-grade cutaneous immune-related adverse events."	( A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Geskin, L; Lopez, AT, 2018)	0.48
" Safety and treatment emergent adverse events (AEs) evaluated throughout."	( Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials. Bagel, J; Cook-Bolden, FE; Green, LJ; Israel, R; Kerdel, FA; Lin, T; Martin, G; Pillai, R; Ramakrishna, T, 2018)	0.48
" Safety and treatment-emergent adverse events (AEs) were evaluated throughout."	( Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies. Harris, S; Lin, T; Martin, G; Pillai, R; Soung, J; Sugarman, JL; Tanghetti, EA; Weiss, JS; Yamauchi, PS, 2019)	0.51
"This study aimed to evaluate the potential adverse effects of the dermal administration of Dillenia indica Linnaeus (D."	( Study of the potential adverse effects caused by the dermal application of Dillenia indica L. fruit extract standardized to betulinic acid in rodents. Carvalho, AC; da Silva, GS; Fernandes, FS; Hilel, AS; Kanis, LA; Kviecinski, MR; Martins, DF; Remor, KVT; Schlindwein, AD, 2019)	0.51
" Safety and treatment emergent adverse events (TEAEs) were evaluated throughout."	( Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019)	0.51
" Because MF is a chronic disease, prolonged treatment is needed, raising the concern of CS-induced cutaneous adverse effects (AEs)."	( Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: an observational study. Geller, S; Myskowski, PL, 2020)	0.99
" The most common treatment-related adverse events were application site reactions of dermatitis, pruritus, pain and irritation."	( Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Han, G; Harris, S; Jacobson, A; Lebwohl, MG; Lin, T; Papp, K; Pariser, DM; Stein Gold, L, 2021)	0.62
" To assess what impact can be expected from this regulatory action, we analyzed reports of adverse drug events due to topical corticosteroids at a hospital-based pharmacovigilance center between January 2017 and August 2018."	( Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough. Asati, DP; Chaudhary, D; Jhaj, R; Sadasivam, B, )	0.13
"45%) were the corticosteroids most frequently associated with adverse events."	( Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough. Asati, DP; Chaudhary, D; Jhaj, R; Sadasivam, B, )	0.13
"Nearly half of the cutaneous adverse effects were due to topical steroid combinations which are still widely available over the counter."	( Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough. Asati, DP; Chaudhary, D; Jhaj, R; Sadasivam, B, )	0.13
" The use of oral NAC and PTX added to the therapeutic efficacy of topical clobetasol in the treatment of LPP, suggesting that they might be beneficial and safe adjuvant therapies and add to the efficacy of topical treatment without any noticeable impact on the adverse effects experienced by patients."	( Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: A triple arm blinded randomized controlled trial. Ahmadi Kahjoogh, H; Behrangi, E; Goodarzi, A; Hejazi, P; Roohaninasab, M; Yazdanian, N, 2022)	1.15
" Patients were visited every 2 months to assess the lichen planopilaris activity index (LPPAI) and record probable adverse events."	( Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: A randomized clinical trial. Azar, PM; Balighi, K; Daneshpazhooh, M; Dasdar, S; Ghiasi, M; Kianfar, N; Lajevardi, V; Peymanfar, AA, 2022)	0.94
" Secondary endpoints included maximum daily and median cumulative doses, reduction in pruritus and occurrence of adverse events."	( Safety and efficacy of high-dose clobetasol propionate 0.05% in cutaneous lichen planus. Bergqvist, C; Bouchereau, S; Condamina, M; Giraud-Kerleroux, L; Guelimi, R; Hirsch, G; Hua, C; Le Cleach, L; Melin, A; Skayem, C; Wolkenstein, P, 2023)	1.19

Excerpt	Reference	Relevance
" It is concluded that steroids in combination with UVB should be used only during the initial period in order to achieve a more rapid alleviation of symptoms and to avoid the side effects."	( The effect on psoriasis of clobetasol propionate used alone or in combination with UVB. Larkö, O; Svartholm, H; Swanbeck, G, 1984)	0.56
"To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis."	( Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Faergemann, J; Kerrouche, N; Lee, JH; Nikkels, AF; Ortonne, JP; Ponce Olivera, RM; Reich, K; Sidou, F, 2011)	0.59
"In this 12-week study, patients with moderate to severe psoriasis received twice weekly treatment with XTRAC® Velocity 308-nm excimer laser combined with clobetasol propionate twice daily followed by calitriol ointment twice daily."	( Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study. Brown, G; Butler, D; Debbaneh, M; Gupta, R; Huynh, M; Koo, JY; Leon, A; Levin, E; Malakouti, M; Wang, E, 2015)	0.86
"Excimer laser therapy combined with an optimized topical regimen that includes clobetasol spray followed by calictriol ointment appears to be an effective treatment for moderate to severe generalized psoriasis that avoids the risk of serious internal side effects associated with many systemic agents."	( Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study. Brown, G; Butler, D; Debbaneh, M; Gupta, R; Huynh, M; Koo, JY; Leon, A; Levin, E; Malakouti, M; Wang, E, 2015)	0.89
" In this 12-week study, patients with moderate to severe psoriasis received twice weekly treatments with a 308-nm excimer laser combined with clobetasol proprionate twice daily for a month followed by calcitriol ointment twice daily for the next month."	( An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis. Beroukhim, K; Danesh, MJ; Koo, J; Leon, A; Levin, E; Nguyen, CM, 2016)	0.86
"To assess the therapeutic effect of fractional CO2 laser resurfacing in combination with potent topical corticosteroids on hypertrophic burn scars in pediatric age group."	( Fractional Carbon Dioxide Laser Resurfacing in Combination With Potent Topical Corticosteroids for Hypertrophic Burn Scars in the Pediatric Age Group: An Open Label Study. Imran, S; Majid, I, 2018)	0.48
"Fractional CO2 laser resurfacing in combination with potent topical steroids leads to significant therapeutic benefits in children with postburn hypertrophic scars."	( Fractional Carbon Dioxide Laser Resurfacing in Combination With Potent Topical Corticosteroids for Hypertrophic Burn Scars in the Pediatric Age Group: An Open Label Study. Imran, S; Majid, I, 2018)	0.48
"Isotretinoin combined with topical treatments is more effective than monotherapy with clobetasol and tacrolimus for FFA."	( Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial. Abedini, R; Amini, M; Daneshpazhooh, M; Mahmoudi, H; Nili, A; Rostami, A; Salehi Farid, A; Tavakolpour, S; Teimourpour, A, 2022)	1.21

Excerpt	Reference	Relevance
"Twelve percent ammonium lactate produced a significant sparing of atrophy in both the epidermis and dermis without any influence on the bioavailability or antiinflammatory properties of the corticosteroid."	( Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. Kaidbey, K; Lavker, RM; Leyden, JJ, 1992)	0.28
"This study describes the bioavailability of Clobetasone, which is topically applied as an anti-inflammatory drug."	( Distribution of clobetasone in rabbit eye tissues after topical application. Connors, B; Hockwin, O; Rink, H; Umlauf, A; Wegener, A, 1989)	0.28
"In order to quantify the intensity of skin blanching and thus predict the bioavailability of topical corticoids, a physical device allowing the measurement of light reflected from skin without any contact between the probe and the skin was used (Leveque et al."	( Objective determination of the bioavailability of dermocorticoids--influence of the formulation. Le Gall, F; Leveque, JL; Poelman, MC, 1984)	0.27
" Their potency and bioavailability are tested with different methods."	( Evaluation of the vasoconstrictive effects of topical steroids by laser-Doppler-perfusion-imaging. Kessels, A; Neumann, M; Sommer, A; Veraart, J, 1998)	0.3
"The concentration of clobetasol propionate in the stratum corneum after application of three different formulations was determined, quantifying the influence of the formulations on the bioavailability of the drug."	( Bioavailability of clobetasol propionate-quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape stripping. Hagemeister, T; Lademann, J; Lindscheid, M; Molzahn, R; Schaefer, H; Schaefer, M; Shah, VP; Sterry, W; v Pelchrzim, R; Weigmann, H, )	0.78
" It was reported that the absorption rate of clobetasol was greater from the foam than from the solution in cadaver skin."	( Clobetasol propionate foam, 0.05%. Jarvis, B; Melian, EB; Spencer, CM, 2001)	2.01
" Differences in corticosteroid bioavailability could account for differences in efficacy."	( Bioavailability of clobetasol propionate in different vehicles. Feldman, SR; Franz, TJ; Lehman, PA; Spellman, MC, )	0.46
" The purpose of the study was to investigate the topical bioavailability of different topical corticosteroid formulations in healthy human beings focussing on desoximetasone (DM)."	( Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. Borelli, C; Fluhr, JW; Gassmueller, J; Korting, HC; Nietsch, KH; Schinzel, S, 2008)	0.35
" Good topical bioavailability of both DM formulations was detected by chromametric measurement and clinical assessment."	( Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. Borelli, C; Fluhr, JW; Gassmueller, J; Korting, HC; Nietsch, KH; Schinzel, S, 2008)	0.35
"Dermal microdialysis was used to assess the bioavailability of a topical corticosteroid, clobetasol propionate, following application onto the skin of human subjects."	( Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Au, WL; Benfeldt, E; Kanfer, I; Skinner, MF; Verbeeck, RK, 2012)	0.83
" However, despite being effective, its low and variable bioavailability prompt for development of novel carrier that could effectively target CP to site of action without producing undesirable side-effects."	( Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo--part II: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies. Barot, BS; Parejiya, PB; Patel, HK; Shelat, PK; Shukla, A, 2014)	0.73
"To compare the sensitivity of a pharmacokinetic assay, the in vitro permeation test (IVPT), with that of a pharmacodynamic assay, the human skin blanching or vasoconstrictor (VC) assay, in assessing the relative bioavailability of topical clobetasol propionate products."	( Assessing topical bioavailability and bioequivalence: a comparison of the in vitro permeation test and the vasoconstrictor assay. Franz, TJ; Lehman, PA, 2014)	0.58
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"The inflammatory dose-response to anthralin was measured in human skin 24 h after pretreatment with topical corticosteroids and anthralin, and 48 h after removal of the stratum corneum with adhesive tape."	( Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum. Lawrence, CM; Shuster, S, 1985)	0.27
" Dose-response data for dilutions of clobetasol propionate and betamethasone 17-valerate showed progressive diminution of both local and systemic effects with decreasing concentrations."	( The effect on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis. Clement, M; du Vivier, A; Hehir, M; Phillips, H, 1983)	0.54
" Initially, the dose-response relationship was established for each agent by applying a series of five doses (0."	( Fluorescence spectroscopy: a rapid, noninvasive method for measurement of skin surface thickness of topical agents. Diffey, BL; Rhodes, LE, 1997)	0.3
" Even when steroids are for external use, their dosage and administration should be monitored, and the risk of ONF should also be considered."	( Osteonecrosis of the femoral head that developed after long-term topical steroid application. Hirasawa, Y; Kojima, A; Kubo, T; Ueshima, K; Yamamoto, T; Yamazoe, S, 2001)	0.31
" Laser Doppler perfusion imaging (LDPI) data can be combined with dosimetry data to produce objective dose-response plots in addition to the MED."	( Phototesting with a divergent UVB beam in the investigation of anti-inflammatory effects of topically applied substances. Anderson, C; Falk, M; Ilias, MA; Wårdell, K, 2003)	0.32
" The reaction diameter, the mean perfusion, and the average dose-response plots for each group and treatment were extracted from the LDPI data."	( Phototesting with a divergent UVB beam in the investigation of anti-inflammatory effects of topically applied substances. Anderson, C; Falk, M; Ilias, MA; Wårdell, K, 2003)	0.32
" Analysis of the dose-response data at doses higher than the MED showed a linear relationship (0."	( Phototesting with a divergent UVB beam in the investigation of anti-inflammatory effects of topically applied substances. Anderson, C; Falk, M; Ilias, MA; Wårdell, K, 2003)	0.32
"The divergent beam protocol can be used to demonstrate and quantify the effects of topical agents on the UVB reaction, in terms of reaction diameter, mean perfusion and changes in dose-response characteristics."	( Phototesting with a divergent UVB beam in the investigation of anti-inflammatory effects of topically applied substances. Anderson, C; Falk, M; Ilias, MA; Wårdell, K, 2003)	0.32
"2) with the same dosage regimen."	( A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, rand Aricò, P; Campisi, G; De Caro, V; Di Liberto, C; Giandalia, G; Giannola, LI, 2004)	0.63
"Using the visual score, we found dose-response blanching at all concentrations of clobetasol propionate."	( Evaluation of the effects of topical clobetasol propionate by visual score, electrical impedance and laser Doppler flowmetry. Emtestam, L; Kuzmina, N; Talme, T, 2007)	0.84
" Seven different dosage forms are available to deliver the drug to the living cells of the skin."	( Clobetasol propionate--where, when, why? Lademann, J; Pels, R; Sterry, W, 2008)	1.79
" For example, a new formulation of calcipotriene/betamethasone scalp solution has a rapid onset of action with once daily dosing that improves compliance."	( Scalp psoriasis. Kircik, LH; Kumar, S, 2010)	0.36
" Conventional dosage forms like creams and ointments are commonly prefered for the therapy."	( Microparticulate based topical delivery system of clobetasol propionate. Badıllı, U; Sen, T; Tarımcı, N, 2011)	0.62
"A 28-year-old man with decreased libido received ashwagandha in the usual daily dosage of 5 g for 10 days."	( Fixed-drug eruption caused by ashwagandha (Withania somnifera): a widely used Ayurvedic drug. Bhattacharya, SN; Sehgal, VN; Verma, P, )	0.13
"A novel, sensitive, stability-indicating, gradient, reverse-phase high-performance liquid chromatographic method has been developed for quantitative determination of halobetasol propionate and its impurities in topical dosage forms."	( Quantification of halobetasol propionate and its impurities present in topical dosage forms by stability-indicating LC method. Kulkarni, D; Nalwade, S; Reddy, VR; Todamal, S, 2015)	0.42
"To study the reservoir effect of topical steroids in a steroid-responsive condition which may enable a decrease in the dosing frequency of topical steroids."	( The reservoir effect of topical steroids in vitiliginous skin: A cross-sectional study. Nasir, F; Singh, SK, )	0.13
" Self-medication and poor adherence to dosage recommendations were noted in the patient's medical history."	( [Oral hairy leukoplakia induced by topical steroids]. Boulanger, M; Fricain, JC; Projetti, F; Sibaud, V; Vigarios, E, 2015)	0.42
"Attempts to use topical cyclosporine in treatment of psoriasis have failed because of unfavorable physicochemical properties and inappropriate formulation design of the conventional dosage forms."	( Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial. Amarji, B; Dogra, S; Katare, OP; Kumar, R; Kumar, S; Mahajan, R; Singh, B; Vinay, K, 2016)	0.43
"The aim of this research was the development and characterization of three gel dosage forms of Halobetasol propionate loaded lipid nanoparticles (HB-NLC) for the treatment of inflammatory skin diseases."	( Nanostructured lipid carriers loaded with Halobetasol propionate for topical treatment of inflammation: Development, characterization, biopharmaceutical behavior and therapeutic efficacy of gel dosage forms. Araya, C; Calpena, AC; Carvajal-Vidal, P; Espina, M; García, ML; Gómez de Aranda, I; González-Pizarro, R; Halbaut, L, 2020)	0.56
" The DPE 3D printing of these dosage forms can allow the reduction of frequency regimen, the therapy personalization, and reduction of oral cavity administration discomfort."	( 3D printed mucoadhesive orodispersible films manufactured by direct powder extrusion for personalized clobetasol propionate based paediatric therapies. Arduino, I; Cilurzo, F; Denora, N; Lopalco, A; Lopedota, A; Meazzini, C; Musazzi, UM; Pistone, M; Racaniello, GF; Rizzi, R, 2023)	1.13

Role	Description
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
SMO receptor agonist	An agonist that enhances the action of smoothened (SMO) receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
17alpha-hydroxy steroid	The alpha-stereoisomer of 17-hydroxy steroid.
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
glucocorticoid	Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
fluorinated steroid	A steroid which is substituted with one or more fluorine atoms in any position.
3-oxo-Delta(1),Delta(4)-steroid	A 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
chlorinated steroid	A steroid which is substituted with one or more chlorine atoms in any position.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	0.0531	0.0008	11.3822	44.6684	AID686978
AR protein	Homo sapiens (human)	Potency	4.0081	0.0002	21.2231	8,912.5098	AID743035; AID743036; AID743040; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0016	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	0.3786	0.0002	29.3054	16,493.5996	AID743069; AID743078
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	21.3138	0.0010	19.4141	70.9645	AID743140
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	10.0078	0.0007	23.0674	1,258.9301	AID743085; AID743122
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1664332	Inhibition of LPS-induced TNFalpha release in human PBMC cells relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1664339	Inhibition of PHA-induced IL4 release in human PBMC cells	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID1664331	Inhibition of LPS-induced TNFalpha release in human PBMC cells	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1664334	Inhibition of LPS-induced IL12p40 release in human PBMC cells relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1664335	Inhibition of PHA-induced IL2 release in human PBMC cells	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID729901	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
AID1664340	Inhibition of PHA-induced IL4 release in human PBMC cells relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID729897	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release at 100 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
AID729899	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL6 release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
AID729900	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1702763	Antiinflammatory activity against imiquimod-induced psoriasis BALB/c mouse model assessed as body weight loss at 0.02 % applied topically once daily for 12 days	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1664338	Inhibition of PHA-induced IFNgamma release in human PBMC cells relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID1664337	Inhibition of PHA-induced IFNgamma release in human PBMC cells	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1664336	Inhibition of PHA-induced IL2 release in human PBMC cells relative to control	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID729896	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL6 release at 100 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
AID1664333	Inhibition of LPS-induced IL12p40 release in human PBMC cells	2020	Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16	Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID729898	Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release at 100 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	211 (14.85)	18.7374
1990's	220 (15.48)	18.2507
2000's	344 (24.21)	29.6817
2010's	502 (35.33)	24.3611
2020's	144 (10.13)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	389 (25.39%)	5.53%
Reviews	118 (7.70%)	6.00%
Case Studies	520 (33.94%)	4.05%
Observational	4 (0.26%)	0.25%
Other	501 (32.70%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (109)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial [NCT03535233]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
Investigating Anti-inflammatory Effects of Topical Antibiotics in an LPS Skin Challenge Model [NCT03779360]		32 participants (Actual)	Interventional	2018-10-12	Completed
Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis [NCT01205880]	Phase 4	12 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid [NCT03286582]	Phase 2	10 participants (Actual)	Interventional	2017-09-05	Terminated(stopped due to Terminated with partial enrollment completed)
Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid [NCT02313870]	Phase 3	322 participants (Actual)	Interventional	2008-01-22	Completed
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid [NCT06148090]		50 participants (Anticipated)	Interventional	2023-11-22	Not yet recruiting
A Randomised, Double-blind (for GW870086), Placebo-controlled Study of Topical GW870086 Formulation to Explore the Potential for Skin Thinning in Healthy Adult Volunteers [NCT01381445]	Phase 1	20 participants (Actual)	Interventional	2011-04-14	Completed
Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery [NCT02487212]	Phase 4	24 participants (Actual)	Interventional	2014-04-30	Completed
A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP) [NCT01282515]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2011-08-31	Completed
A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin [NCT02392130]	Phase 1	40 participants (Actual)	Interventional	2015-03-31	Completed
Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus [NCT03386643]	Phase 2	22 participants (Actual)	Interventional	2017-11-06	Completed
A Phase 3, Multicenter, Randomized, Evaluator-blinded Clinical Trial to Assess the Safety and Efficacy of Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% Compared to Prednisolone Acetate, 1% in the Treatment of Inflammation After Cataract Surgery in [NCT05724446]	Phase 3	60 participants (Anticipated)	Interventional	2022-12-12	Recruiting
Comparative Efficacy of Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata [NCT05885269]	Phase 1	70 participants (Actual)	Interventional	2022-11-01	Completed
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days [NCT02635204]	Phase 3	267 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized, Unblinded Trial of Topical Steroids Plus CO2 Laser Compared to Steroids Alone in the Treatment of Vulvovaginal Lichen Sclerosus [NCT05243563]	Phase 2/Phase 3	52 participants (Anticipated)	Interventional	2022-04-13	Recruiting
A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis [NCT03058744]	Phase 1	94 participants (Actual)	Interventional	2015-04-30	Completed
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia [NCT01111981]	Phase 4	30 participants (Anticipated)	Interventional	2009-10-31	Recruiting
Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid [NCT03926377]	Phase 4	50 participants (Anticipated)	Interventional	2019-04-01	Recruiting
A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) [NCT02319616]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Lack of enrollment)
An Open Label Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for the Condition of Chronic Hand Dermatitis [NCT00828464]	Phase 4	30 participants (Actual)	Interventional	2008-10-31	Completed
Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis [NCT03453190]	Phase 4	20 participants (Anticipated)	Interventional	2018-02-25	Recruiting
A 28-day, Double-blind, Randomized, Reference-controlled Open Psoriasis Plaque Test for Within Subject Comparison of Efficacy and Safety of Mapracorat 0.1% Ointment and 4 Reference Products in Symptomatic Volunteers With Stable Plaque-type Psoriasis [NCT03399526]	Phase 1	24 participants (Actual)	Interventional	2013-02-11	Completed
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) to Duobrii® Lotion (Halobetasol Propionate and Tazarotene L [NCT05282771]	Early Phase 1	402 participants (Actual)	Interventional	2021-04-16	Completed
Clinical Trial of Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis Plate, and as Comparator the Product Psorex (Clobetasol Propionate). [NCT00715975]	Phase 2/Phase 3	140 participants (Anticipated)	Interventional	2008-07-31	Completed
A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate Ointment With Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Plaque Psoriasis [NCT00733954]	Phase 4	250 participants (Actual)	Interventional	2007-08-31	Completed
An Open-label, Multi-center, Randomized, Evaluator-Blinded Study to Evaluate the Safety and Efficacy of Two Treatment Regimens Involving Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05% in the Treatment of Moderate P [NCT00988637]	Phase 4	138 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study [NCT02492373]		21 participants (Actual)	Interventional	2015-02-28	Completed
An Open-label Safety Study to Assess the Multiple-dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray Applied Twice Daily for 28 Days in Patients With Moderate to Severe P [NCT03298581]	Phase 2	0 participants (Actual)	Interventional	2017-01-01	Withdrawn(stopped due to Sponsor decision)
Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers [NCT03878771]	Phase 1	804 participants (Actual)	Interventional	2019-03-13	Completed
A Multicenter Randomized Double-blind Placebo-controlled Parallel Group Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 Cream Used in the Treatment of Mild to Moderate Plaque Psoriasis [NCT05706870]	Phase 2	190 participants (Actual)	Interventional	2022-12-07	Active, not recruiting
Monocentric, Prospective, Randomised, Single Blinded, Active-controlled Trial to Prove That the Treatment With Monalisa Glide is Equal to Topic Clobetasol Propionate Maintenance Therapy in Vulvar Lichen Sclerosus [NCT06135402]		120 participants (Anticipated)	Interventional	2023-11-10	Recruiting
A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis [NCT06042647]	Phase 4	10 participants (Actual)	Interventional	2023-07-13	Completed
A Psoriasis Plaque Study Comparing Clobetasol Propionate Plus Calcipotriol Ointment With Clobetasol Propionate Ointment Alone, Calcipotriol Ointment Alone and a Vehicle Control for the Treatment of Psoriasis Vulgaris [NCT01043224]	Phase 1	24 participants (Actual)	Interventional	2010-01-31	Completed
Pilot Study of Vulvar Lichen Sclerosus (VLS) Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma (PRP). [NCT03961126]	Phase 2	20 participants (Actual)	Interventional	2017-09-06	Completed
A Randomized Controlled Trial of Vulvar Fractionated CO2-Laser Therapy With and Without Concomitant Topical Clobetasol Propionate 0.05% Ointment for Treatment of Vulvar Lichen Sclerosus [NCT04951206]	Phase 4	184 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus- A Double-blinded Randomized Clinical Trial in Sri Lanka [NCT02744378]	Phase 2	68 participants (Actual)	Interventional	2014-06-30	Completed
A Phase 3, Multicenter, Randomized, Double-Masked Clinical Trial to Assess the Efficacy and Safety of Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% Compared to Placebo in the Treatment of Inflammation and Pain Associated With Cataract Surgery [NCT04249076]	Phase 3	215 participants (Actual)	Interventional	2020-06-04	Completed
Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream (Elidel® 1% Cream), Hydrocortisonacetat 1% Cream (Hydrogalen® Cream), Betamethasonvalerat 0,1% Cream (Betagalen® Cream) and Clobetasol-17-propionat 0,05% Cream (Clobegalen® Cream) Ass [NCT00655512]	Phase 1	40 participants (Actual)	Interventional	2008-01-31	Completed
A Multi-Center, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Clobetasol Propionate Spray Versus Vehicle for the Management of Moderate to Severe Plaque Psoriasis of the Scalp [NCT00881868]	Phase 4	81 participants (Actual)	Interventional	2009-04-30	Completed
[NCT01946386]	Phase 1	35 participants (Actual)	Interventional	2013-09-30	Completed
A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients With Moderate-to-Severe Localized Psoriasis Lesions: a Pilot Study. [NCT00769184]		15 participants (Actual)	Interventional	2008-10-31	Completed
Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment [NCT01012713]	Phase 4	30 participants (Actual)	Interventional	2010-06-30	Completed
A Phase 3, Multicenter, Randomized, Double-Masked Clinical Trial to Assess the Efficacy and Safety of Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% Compared to Placebo in the Treatment of Inflammation and Pain Associated With Cataract Surgery [NCT04246801]	Phase 3	250 participants (Actual)	Interventional	2020-06-10	Completed
Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea [NCT02680717]	Phase 1	0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to Unable to obtain IRB approval at all sites)
[NCT01166646]	Phase 2	43 participants (Actual)	Interventional	2010-07-31	Completed
Bioequivalence of Two Clobetasol Propionate 0.05% Topical Foams [NCT00803439]		80 participants (Actual)	Observational	2005-04-30	Completed
[NCT02733874]	Phase 4	240 participants (Actual)	Interventional	2015-04-30	Completed
A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study [NCT00865605]	Phase 1	71 participants (Actual)	Interventional	2003-12-31	Completed
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy [NCT01407471]	Phase 2	26 participants (Actual)	Interventional	2011-09-30	Completed
Bioequivalence of Two Clobetasol Propionate 0.05% Topical Lotions [NCT00864500]	Phase 1	224 participants (Actual)	Interventional	2005-11-30	Completed
Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis [NCT00862654]	Phase 3	326 participants (Actual)	Interventional	2009-03-31	Completed
A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus. [NCT00757874]	Phase 2	56 participants (Actual)	Interventional	2006-04-30	Completed
A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of a Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray, Followed by Calcitriol Ointment 3µg/g, in the Management of Moderate to Severe Plaque Psoriasis [NCT00658788]	Phase 3	305 participants (Actual)	Interventional	2008-03-31	Completed
Bioequivalence of Three Halobetasol Propionate 0.05% Topical Creams [NCT00803166]		60 participants (Actual)	Observational	2004-01-31	Completed
Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation [NCT00779792]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Dose Response of Clobex 0.05% Lotion [NCT00864240]	Phase 1	15 participants (Actual)	Interventional	2005-10-31	Completed
Dupilumab Impact on Skin Resident Memory T Cells [NCT03983460]		20 participants (Anticipated)	Interventional	2020-03-09	Recruiting
DRESS - Setting of Corticosteroid Treatment. [NCT01987076]		112 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial. [NCT04364555]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2020-05-18	Recruiting
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis [NCT01235442]	Phase 3	592 participants (Actual)	Interventional	2010-09-30	Completed
Evaluation of Topical Rebamipide Versus Topical Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients: Randomized-Controlled Clinical Trial [NCT04649697]	Phase 3	39 participants (Anticipated)	Interventional	2020-12-01	Recruiting
A 28-day, Double-blind, Randomized, Reference-controlled Psoriasis Plaque Test to Evaluate the Efficacy and Safety of Two Different BAY1003803 Formulation Types in 2 Concentrations Each in Treatment of Symptomatic Volunteers With Plaque-type Psoriasis [NCT02940002]	Phase 1	23 participants (Actual)	Interventional	2016-10-12	Completed
A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis [NCT00842153]	Phase 4	58 participants (Actual)	Interventional	2007-11-30	Completed
Bioequivalence of Two Halobetasol Propionate 0.05% Topical Ointments [NCT00802958]		76 participants (Actual)	Observational	2003-07-31	Completed
A Double-Blind, Parallel-group Trial of Topical Pimecrolimus Cream 1% (Elidel®) Versus Clobetasol 0.05% Cream for the Treatment of Vulvar Lichen Sclerosus [NCT00393263]	Phase 2	38 participants (Actual)	Interventional	2006-10-31	Completed
A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids [NCT05348200]	Phase 2	304 participants (Actual)	Interventional	2022-04-22	Completed
A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis [NCT00990561]	Phase 4	40 participants (Actual)	Interventional	2009-07-31	Completed
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. [NCT01323673]	Phase 4	125 participants (Actual)	Interventional	2010-11-15	Completed
Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled De [NCT02936492]	Phase 1	32 participants (Actual)	Interventional	2016-10-24	Terminated
Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis [NCT04685031]	Phase 1/Phase 2	110 participants (Anticipated)	Interventional	2021-02-01	Not yet recruiting
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC) [NCT02368886]	Phase 2	123 participants (Actual)	Interventional	2015-03-27	Completed
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion (0.01% Halobetasol Propionate) to Ultravate® (Halobetasol Propionate) Cream, in the Treatment of Plaque Psoriasis [NCT02785185]	Phase 2	150 participants (Actual)	Interventional	2016-06-30	Completed
Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-week Daily Course of Clobex® Shampoo 0.05% [NCT00400725]	Phase 3	288 participants (Actual)	Interventional	2006-09-29	Completed
CO2 Non-ablative Laser Versus Topical Clobetasol for Lichen Sclerosus: a Prospective, Open-label, Randomized Trial [NCT05010421]	Phase 3	198 participants (Anticipated)	Interventional	2021-11-02	Recruiting
A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. [NCT00852761]	Phase 4	34 participants (Actual)	Interventional	2009-03-31	Completed
Valacyclovir+Temovate Gel for the Episodic Treatment of Herpes Labialis: A Patient-Initiated Double-Blind, Placebo-Controlled Study, Randomized Study. [NCT00297011]	Phase 2	300 participants	Interventional	2004-09-30	Completed
A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects [NCT03758365]	Phase 1	36 participants (Actual)	Interventional	2018-11-05	Completed
Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients [NCT01699412]	Phase 3	28 participants (Actual)	Interventional	2008-08-31	Completed
Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment [NCT01703325]	Phase 4	16 participants (Actual)	Interventional	2010-11-30	Completed
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis [NCT00470392]		9 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Recruiting complete and administrative termination)
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% [NCT01893567]	Phase 4	28 participants (Actual)	Interventional	2013-07-31	Completed
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study [NCT04207931]	Phase 4	250 participants (Anticipated)	Interventional	2018-04-30	Recruiting
Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis [NCT03847389]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2019-09-09	Terminated(stopped due to Difficulty in enrollment and COVID-19 pandemic.)
Efficacy of a Topic Therapy With Progesterone Compared to the Conventional Therapy With Clobetasol Propionate in Patients With Vulvar Lichen Sclerosus. A Double Blind, Randomized Phase II Pilot Study. [NCT01126255]	Phase 2	37 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Recruitment problems)
Phase 4 Open-Label Multicenter Community-based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis [NCT00437216]		2,488 participants (Actual)	Observational	2006-02-28	Completed
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-Disease [NCT01557517]	Phase 2	40 participants (Actual)	Interventional	2012-01-26	Completed
An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis [NCT00437255]	Phase 4	122 participants (Actual)	Interventional	2006-08-31	Completed
Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN) [NCT05608499]	Phase 3	30 participants (Anticipated)	Interventional	2022-10-26	Recruiting
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis [NCT01745133]	Phase 4	63 participants (Actual)	Interventional	2013-01-31	Completed
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment [NCT03212963]	Phase 4	16 participants (Actual)	Interventional	2017-03-21	Terminated(stopped due to Sponsor's Decision)
A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata [NCT01453686]	Phase 3	41 participants (Actual)	Interventional	2002-08-31	Completed
Randomized Clinical Trial, Controlled to Conventional Treatment, to Evaluate the Efficacy of Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva [NCT05364515]	Phase 3	30 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Prospective, Randomized, Active-controlled Investigator Initiated Clinical Trial to Demonstrate That the Nd:YAG/Er:YAG Dual Laser Therapy is Effective to Treat Vulvar Lichen Sclerosus and Similar to Standard Treatment With Steroid Cream [NCT03926299]		66 participants (Actual)	Interventional	2019-07-15	Active, not recruiting
Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle [NCT02973776]	Phase 1	36 participants (Actual)	Interventional	2016-12-31	Completed
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis [NCT02785172]	Phase 2	154 participants (Actual)	Interventional	2016-04-30	Completed
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid [NCT02360202]	Phase 4	35 participants (Anticipated)	Interventional	2015-04-30	Recruiting
A Randomized Trial of Clobetasol Propionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus (CuRLS) [NCT02573883]	Phase 3	52 participants (Actual)	Interventional	2015-10-31	Completed
Vulvar Lichen Sclerosus: Therapeutic Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser [NCT02416531]		30 participants (Actual)	Interventional	2015-01-31	Completed
Evaluation of the Efficacy of Supplementary Probiotic Capsules With Topical Clobetasol Propionate 0.05% in the Treatment of Oral Lichen Planus [NCT06119672]	Phase 3	36 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus: a Randomized Clinical Trial [NCT05818618]		64 participants (Actual)	Interventional	2020-03-12	Completed
An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis [NCT02376049]	Phase 1	30 participants (Actual)	Interventional	2015-02-28	Completed
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days [NCT02445807]	Phase 3	265 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate When Administered Intra-orally Twice Daily in Patients With Oral Lichen Planus (OLP) Using Rivelin®-CLO [NCT03592342]	Phase 2	140 participants (Actual)	Interventional	2018-06-28	Completed
A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis [NCT00436540]	Phase 4	78 participants (Actual)	Interventional	2006-03-31	Completed
Efficacy of Photobiomodulation for Oral Lichen Planus Treatment [NCT03320460]		44 participants (Anticipated)	Interventional	2018-11-01	Recruiting
A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus [NCT03026478]	Phase 2	30 participants (Anticipated)	Interventional	2016-05-06	Recruiting
A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin [NCT02355639]	Phase 1	16 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, Open Label, Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption With DFD-06 Cream Versus Clobetasol Propionate Cream, 0.05% in Subjects With Moderate to Severe Plaque Psoriasis [NCT02131324]	Phase 2	50 participants (Actual)	Interventional	2014-05-08	Completed
An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 in Pediatric Subjects With Moderate to Severe Plaque Psoriasis [NCT03179605]	Phase 2	22 participants (Actual)	Interventional	2017-05-02	Terminated(stopped due to Difficulty in enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00400725 (8) [back to overview]	Maintenance Phase: Time to First Relapse
NCT00400725 (8) [back to overview]	Initial Phase: Percentage of Participants With Global Severity Scores
NCT00400725 (8) [back to overview]	Initial Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores
NCT00400725 (8) [back to overview]	Initial Phase: Percentage of Participants With Pruritus Scores
NCT00400725 (8) [back to overview]	Maintenance Phase: Percentage of Participants Who Had First Relapse
NCT00400725 (8) [back to overview]	Maintenance Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores at First Time of Relapse
NCT00400725 (8) [back to overview]	Maintenance Phase: Percentage of Participants With Number of Relapses Experienced
NCT00400725 (8) [back to overview]	Maintenance Phase: Percentage of Participants With Scalp Psoriasis Pruritus Score at First Time of Relapse
NCT00470392 (3) [back to overview]	Number of Subjects With Improvement in Lesional Psoriasis Area and Assessment (PASI) Score After Imiquimod and UVB Treatment
NCT00470392 (3) [back to overview]	Number of Subjects With Elevated MyxA
NCT00470392 (3) [back to overview]	Number of Subjects With a 1.5 Fold Increase in mRNA Expression of GRAMD1A and DMXL2
NCT00658788 (12) [back to overview]	Signs of Psoriasis - Plaque Elevation
NCT00658788 (12) [back to overview]	Signs of Psoriasis - Erythema
NCT00658788 (12) [back to overview]	Overall Disease Severity
NCT00658788 (12) [back to overview]	Global Improvement Score
NCT00658788 (12) [back to overview]	Percent Change From Baseline in Body Surface Area (% BSA) Affected
NCT00658788 (12) [back to overview]	Tolerability Assessment - Telangiectasias
NCT00658788 (12) [back to overview]	Tolerability Assessment - Stinging/ Burning
NCT00658788 (12) [back to overview]	Overall Disease Severity Success (ODS)
NCT00658788 (12) [back to overview]	Tolerability Assessment - Skin Atrophy
NCT00658788 (12) [back to overview]	Tolerability Assessment - Pruritus
NCT00658788 (12) [back to overview]	Tolerability Assessment - Folliculitis
NCT00658788 (12) [back to overview]	Signs of Psoriasis - Scaling
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to After Two Weeks of Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to After Two Weeks of Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to End of Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to Two Weeks Post Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to After Two Weeks of Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to End of Treatment
NCT00733954 (19) [back to overview]	Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to Two Weeks Post Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to End of Treatment
NCT00733954 (19) [back to overview]	Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to 2 Weeks Post Treatment Based on the Overall Disease Severity (ODS) Scale
NCT00733954 (19) [back to overview]	Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to After Two Weeks of Treatment Based on the Overall Disease Severity (ODS) Scale
NCT00733954 (19) [back to overview]	Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to After Two Weeks of Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to End of Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to Two Weeks Post Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to Two Weeks Post Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to After Two Weeks of Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to End of Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to Two Weeks Post Treatment
NCT00733954 (19) [back to overview]	Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Weeks Post Treatment
NCT00769184 (2) [back to overview]	Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions
NCT00769184 (2) [back to overview]	Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit.
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips
NCT00828464 (14) [back to overview]	Change in Subject's Visual Analogue Assessment Scale
NCT00828464 (14) [back to overview]	Change in Subject's Visual Analogue Assessment Scale From Baseline to Day 15
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands
NCT00828464 (14) [back to overview]	Proportion of Subjects With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Fingers
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands
NCT00828464 (14) [back to overview]	Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score
NCT00828464 (14) [back to overview]	Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists
NCT00828464 (14) [back to overview]	Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands
NCT00842153 (15) [back to overview]	Number of Participants With a Scaling Score of 0 or 1 at Baseline and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With a Scaling Score of 0 or 1 at Week 2
NCT00842153 (15) [back to overview]	Number of Participants With a Pruritus (Overall) Score of 0 or 1 at Week 2
NCT00842153 (15) [back to overview]	Number of Participants With a Plaque Thickness Score of 0 or 1 at Baseline and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With a Target Lesion Global Improvement (TLGI) Score of 0, 1, or 2 at Weeks 1, 2, and 4
NCT00842153 (15) [back to overview]	Number of Participants With a Score of 0 or 1 for Subject Global Assessment at Baseline and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With a Plaque Thickness Score of 0 or 1 at Week 2
NCT00842153 (15) [back to overview]	Mean Percent Change From Baseline to Week 4 in Pruritus (Target Lesion)
NCT00842153 (15) [back to overview]	Mean Percent Change From Baseline to Week 2 in Pruritus (Target Lesion)
NCT00842153 (15) [back to overview]	Number of Participants With an Erythema Score of 0 or 1 at Week 2
NCT00842153 (15) [back to overview]	Number of Participants With a Score of 0 or 1 for Subject Global Assessment at Week 2
NCT00842153 (15) [back to overview]	Number of Participants With a Pruritus (Overall) Score of 0 or 1 at Baseline and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With an Erythema Score of 0 or 1 at Baseline and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With a TLGI Score of 0, 1, or 2 at Week 1 and Week 4
NCT00842153 (15) [back to overview]	Number of Participants With a TLGI Score of 0, 1, 2, or 3 at Weeks 1, 2, and 4
NCT00852761 (19) [back to overview]	At Least 1 Grade Improvement in the Psoriasis Global Assessment
NCT00852761 (19) [back to overview]	At Least 1 Grade Improvement in Subject's Global Assessment
NCT00852761 (19) [back to overview]	At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)
NCT00852761 (19) [back to overview]	At Least a 2 Grade Improvement in the Psoriasis Global Assessment
NCT00852761 (19) [back to overview]	At Least a 3 Grade Improvement in Subject's Global Assessment
NCT00852761 (19) [back to overview]	At Least a 3 Grade Improvement in the Psoriasis Global Assessment
NCT00852761 (19) [back to overview]	At Least a 2 Grade Improvement Psoriasis Grading Scale
NCT00852761 (19) [back to overview]	Dermatology Life Quality Index (DLQI) Categories
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Daily Activities
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Leisure
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Personal Relationships
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Symptoms and Feelings
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Treatment
NCT00852761 (19) [back to overview]	Dermatology Quality of Life - Work and School
NCT00852761 (19) [back to overview]	Median Change in Psoriasis Grading Scale
NCT00852761 (19) [back to overview]	Total Dermatology Life Quality Index (DLQI) Score
NCT00852761 (19) [back to overview]	At Least a 2 Grade Improvement in Subject's Global Assessment
NCT00852761 (19) [back to overview]	At Least 1 Grade Improvement Psoriasis Grading Scale
NCT00852761 (19) [back to overview]	At Least a 3 Grade Improvement Psoriasis Grading Scale
NCT00862654 (1) [back to overview]	Total Severity Score (TSS): Percent Change From Baseline at Week 4
NCT00881868 (4) [back to overview]	Number of Participants in Each Category of the Scalp Psoriasis Individual Sign Scores (Scaling, Erythema and Plaque Elevation) at Baseline and Week 4
NCT00881868 (4) [back to overview]	Number of Participants in Each Category of the Extent of Scalp Involvement Index at Baseline and Week 4
NCT00881868 (4) [back to overview]	Number of Participants in Each Category of Pruritus at Baseline and Week 4
NCT00881868 (4) [back to overview]	Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if Clear)
NCT00988637 (13) [back to overview]	Median Percent (%) Change From Baseline in % Treatable BSA (Body Surface Area) From Baseline to Week 4
NCT00988637 (13) [back to overview]	Number of Participants Who Were a Success (Clear/Almost Clear) of Plaque Psoriasis at Week 2 Based on the Overall Disease Severity (ODS), Dichotomized Scale From Baseline to Week 2
NCT00988637 (13) [back to overview]	Number of Participants Who Were a Success (Clear/Almost Clear) of Plaque Psoriasis at Week 4 Based on the Overall Disease Severity (ODS), Full Ordinal Scale From Baseline to Week 4
NCT00988637 (13) [back to overview]	Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Week 4
NCT00988637 (13) [back to overview]	"Number of Participants Who Responded to the Categories of Possible Answers to the Subject's Satisfaction Survey Question I am Satisfied With my Appearance at Week 4"
NCT00988637 (13) [back to overview]	"Number of Participants Who Responded to the Categories of Possible Answers to the Subject's Satisfaction Survey Question I am Satisfied With the Results of This Treatment Program at Week 4"
NCT00988637 (13) [back to overview]	"Number of Participants Who Responded to the Categories of Possible Answers to the Subject's Satisfaction Survey Question I Would Use This Treatment Program Again if Recommended by the Dermatologist at Week 4"
NCT00988637 (13) [back to overview]	"Number of Participants Who Responded to the Categories of Possible Answers to the Subject's Satisfaction Survey Question The Treatment Program Was Easy to Follow at Week 4"
NCT00988637 (13) [back to overview]	Number of Participants in Each Category of the Global Assessment of Improvement (GAI) Scale From Baseline to Week 4
NCT00988637 (13) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) Scores From Baseline to Week 4
NCT00988637 (13) [back to overview]	Number of Participants With Decrease in Signs of Psoriasis (Scaling) Scores From Baseline to Week 4
NCT00988637 (13) [back to overview]	Number of Participants With a Decrease in Signs of Psoriasis (Erythema) Scores From Baseline to Week 4
NCT00988637 (13) [back to overview]	Mean Change From Baseline Scores for the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) From Baseline to Week 4
NCT00990561 (1) [back to overview]	Change in Modified Psoriasis Area Severity Index (PASI) Score
NCT01012713 (3) [back to overview]	A Tertiary Endpoint Will be the Percentage of Patients Achieving 90% Reduction in Psoriasis Area and Severity Index at Week 12.
NCT01012713 (3) [back to overview]	The Secondary Endpoint Will be the Percentage of Patients Achieving a 75% Reduction in Psoriasis Area and Severity Index at Weeks 4 and 8.
NCT01012713 (3) [back to overview]	The Primary Endpoint Will be the Percentage of Patients Achieving a 75% Reduction in the Psoriasis Area and Severity Index at Week 12.
NCT01166646 (6) [back to overview]	Adrenal Suppression Potential
NCT01166646 (6) [back to overview]	"Number of Subjects Whose Signs of Psoriasis Was Designated Success"
NCT01166646 (6) [back to overview]	Pharmacokinetic Properties (Tmax)
NCT01166646 (6) [back to overview]	Pharmacokinetic Properties (Cmax)
NCT01166646 (6) [back to overview]	Pharmacokinetic Properties (AUC)
NCT01166646 (6) [back to overview]	Changes in Disease Severity (Success)
NCT01235442 (7) [back to overview]	sPGA (0,1) at Week 24
NCT01235442 (7) [back to overview]	sPGA (0,1) at Week 12
NCT01235442 (7) [back to overview]	Percent PASI Improvement From Baseline at Week 12
NCT01235442 (7) [back to overview]	PASI 90 at Week 12
NCT01235442 (7) [back to overview]	PASI 75 at Week 24
NCT01235442 (7) [back to overview]	PASI 75 at Week 12
NCT01235442 (7) [back to overview]	Patient Satisfaction at Week 12
NCT01323673 (8) [back to overview]	Percent Change From Baseline in Pruritus, Stinging, Burning, and Pain Scores (Target Hand) at Days 3, 8, and 15
NCT01323673 (8) [back to overview]	Number of Participants With an ISGA (Target Hand) Score of 0 or 1 at Days 3, 8, and 15
NCT01323673 (8) [back to overview]	Number of Participants With an Improvement of at Least 1 Grade in the Subject Global Assessment (SGA) (Target Hand) Score From Baseline to Days 3, 8, and 15
NCT01323673 (8) [back to overview]	Number of Participants With an Improvement of at Least 1 Grade in the ISGA (Target Hand) Score From Baseline to Day 15
NCT01323673 (8) [back to overview]	Number of Participants With an SGA (Target Hand) Score of 0 or 1 at Days 3, 8, and 15
NCT01323673 (8) [back to overview]	Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) (Target Hand) Score From Baseline to Day 15
NCT01323673 (8) [back to overview]	Number of Participants With an Improvement of at Least 1 Grade in the ISGA (Target Hand) Score From Baseline to Day 3 and and to Day 8
NCT01323673 (8) [back to overview]	Number of Participants With an Improvement of at Least 2 Grades in the ISGA (Target Hand) Score From Baseline to Day 3 and to Day 8
NCT01557517 (9) [back to overview]	Percent Change in Participants' Raw Score of Oral cGVHD Related Sensitivity on a 0-10 Rating Scale
NCT01557517 (9) [back to overview]	Time to Maximum Plasma Concentration (Cmax) of Clobetasol
NCT01557517 (9) [back to overview]	Percent Change in Participants' Raw Score of Oral cGVHD Related Pain on a 0-10 Rating Scale
NCT01557517 (9) [back to overview]	Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-versus-host-disease (cGVHD) During a Four-week Treatment Period
NCT01557517 (9) [back to overview]	Plasma Concentrations of Clobetasol Mouth Rinse in cGVHD Patients at Baseline (Day 0) and Day 28
NCT01557517 (9) [back to overview]	Area Under the Plasma Concentration vs Time Curve for All Time Points
NCT01557517 (9) [back to overview]	Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT01557517 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of Clobetasol During Pharmacokinetic Testing
NCT01557517 (9) [back to overview]	Percent Change in Participants' Raw Score of Oral cGVHD Related Dryness on a 0-10 Rating Scale
NCT01745133 (1) [back to overview]	Physician Global Assessement
NCT01893567 (2) [back to overview]	Investigator Reported Target Lesion Severity Score
NCT01893567 (2) [back to overview]	Subject Reported Target Lesion Severity Score.
NCT02131324 (1) [back to overview]	The Percentage of Subjects With HPA Axis Suppression.
NCT02368886 (7) [back to overview]	Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire)
NCT02368886 (7) [back to overview]	Dose Intensity of Regorafenib Received by Patients in the First Two Cycles as Measured by the Percentage of Planned Dose Received
NCT02368886 (7) [back to overview]	Overall Survival (OS)
NCT02368886 (7) [back to overview]	Progression Free Survival (PFS)
NCT02368886 (7) [back to overview]	Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3
NCT02368886 (7) [back to overview]	Time to Progression (TTP)
NCT02368886 (7) [back to overview]	Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles
NCT02445807 (3) [back to overview]	The Percentage of Subjects With Treatment Success at the Day 8 Visit.
NCT02445807 (3) [back to overview]	The Percent Change in Body Surface Area of Psoriasis
NCT02445807 (3) [back to overview]	Efficacy (Percentage of Subjects With Treatment Success)
NCT02573883 (15) [back to overview]	Number of Patients With Adverse Outcomes
NCT02573883 (15) [back to overview]	Number of Patients With Adverse Outcomes
NCT02573883 (15) [back to overview]	Change Objective Provider VAS Visual Analog Scale
NCT02573883 (15) [back to overview]	Change Objective Provider VAS Visual Analog Scale
NCT02573883 (15) [back to overview]	Change Vulvar Symptom Visual Analog Scale (VAS) Score
NCT02573883 (15) [back to overview]	Change Vulvar Symptom Visual Analog Scale (VAS) Score
NCT02573883 (15) [back to overview]	Change in SkinDEX-29 Score
NCT02573883 (15) [back to overview]	Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ)
NCT02573883 (15) [back to overview]	Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ)
NCT02573883 (15) [back to overview]	Change SkinDEX-29 Score
NCT02573883 (15) [back to overview]	Change Vaginal Health Index (VHI) Score
NCT02573883 (15) [back to overview]	Change Vaginal Health Index (VHI) Score
NCT02573883 (15) [back to overview]	Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score
NCT02573883 (15) [back to overview]	Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score
NCT02573883 (15) [back to overview]	Number of Patients With Adverse Outcomes
NCT02635204 (3) [back to overview]	Percent Change From Baseline in Body Surface Area at Day 15
NCT02635204 (3) [back to overview]	Percent of Subjects With Treatment Success at Day 8 Visit
NCT02635204 (3) [back to overview]	Percentage of Subjects With Treatment Success at Day 15
NCT02785172 (1) [back to overview]	Percent of Subjects With Treatment Success
NCT02785185 (1) [back to overview]	Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 2
NCT03179605 (3) [back to overview]	Plasma Concentration of Clobetasol Propionate
NCT03179605 (3) [back to overview]	Percentage of Subjects With HPA Axis Suppression at Day 15
NCT03179605 (3) [back to overview]	Number of Participants With Improvement in IGA Grade From Baseline
NCT03212963 (4) [back to overview]	Number of Subjects With Abnormal Hypothalamus-Pituitary-Adrenal Axis Response
NCT03212963 (4) [back to overview]	Percent Body Surface Area Treated With Test Article
NCT03212963 (4) [back to overview]	Percent BSA Affected With Disease
NCT03212963 (4) [back to overview]	Investigator's Global Assessment
NCT03758365 (2) [back to overview]	Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
NCT03758365 (2) [back to overview]	Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
NCT04246801 (2) [back to overview]	Pain Visual Analogue Scale (VAS) Score
NCT04246801 (2) [back to overview]	Anterior Chamber Cell Grade
NCT04249076 (2) [back to overview]	Pain Visual Analogue Scale (VAS) Score
NCT04249076 (2) [back to overview]	Anterior Chamber Cell Grade

Maintenance Phase: Time to First Relapse

Time to first relapse was defined as the duration between baseline of maintenance phase and the visit where the relapse occurred. The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS >2. (NCT00400725)
Timeframe: Baseline up to 24 Weeks

Intervention	days (Mean)
Maintenance Phase: Clobex® Shampoo	93.5
Maintenance Phase: Clobex® Vehicle Shampoo	56.8

Intervention	percentage of participants (Number)
	Baseline: Score 0 (Clear)	Baseline: Score 1 (Very mild)	Baseline: Score 2 (Mild)	Baseline: Score 3 (Moderate)	Baseline: Score 4 (Severe)	Week 2-LOCF: Score 0 (Clear)	Week 2-LOCF: Score 1 (Very mild)	Week 2-LOCF: Score 2 (Mild)	Week 2-LOCF: Score 3 (Moderate)	Week 2-LOCF: Score 4 (Severe)	Week 4-LOCF: Score 0 (Clear)	Week 4-LOCF: Score 1 (Very mild)	Week 4-LOCF: Score 2 (Mild)	Week 4-LOCF: Score 3 (Moderate)	Week 4-LOCF: Score 4 (Severe)
Initial Phase:- Clobex® Shampoo (Clobetasol Propionate 0.05% [W/W])	0	0	0	58.3	41.7	2.4	10.1	35.4	43.1	9.0	7.6	25.3	45.1	18.4	3.5

Intervention	percentage of participants (Number)
	Erythema at Baseline: Score 0 (None)	Erythema at Baseline: Score 1 (Mild)	Erythema at Baseline: Score 2 (Moderate)	Erythema at Baseline: Score 3 (Severe)	Erythema at Baseline: Score 4 (Very Severe)	Erythema at Week 2 - LOCF: Score 0 (None)	Erythema at Week 2 - LOCF: Score 1 (Mild)	Erythema at Week 2 - LOCF : 2: Moderate	Erythema at Week 2 - LOCF: Score 3 (Severe)	Erythema at Week 2 - LOCF: Score 4 (Very Severe)	Erythema at Week 4 - LOCF: Score 0 (None)	Erythema at Week 4 - LOCF: Score 1 (Mild)	Erythema at Week 4 - LOCF: Score 2 (Moderate)	Erythema at Week 4 - LOCF: Score 3 (Severe)	Erythema at Week 4 - LOCF: Score 4 (Very Severe)	Scaling at Baseline: Score 0 (None)	Scaling at Baseline: Score 1 (Mild)	Scaling at Baseline: Score 2 (Moderate)	Scaling at Baseline: Score 3 (Severe)	Scaling at Baseline: Score 4: (Very Severe)	Scaling at Week 2-LOCF: Score 0 (None)	Scaling at Week 2-LOCF: Score 1 (Mild)	Scaling at Week 2-LOCF: Score 2 (Moderate)	Scaling at Week 2-LOCF: Score 3 (Severe)	Scaling at Week 2-LOCF: Score 4 (Very Severe)	Scaling at Week 4-LOCF: Score 0 (None)	Scaling at Week 4-LOCF: Score 1 (Mild)	Scaling at Week 4-LOCF: Score 2 (Moderate)	Scaling at Week 4-LOCF: Score 3 (Severe)	Scaling at Week 4-LOCF: Score 4 (Very Severe)	Plaque Thickening at Baseline: Score 0 (None)	Plaque Thickening at Baseline: score 1 (Mild)	Plaque Thickening at Baseline: Score 2 (Moderate)	Plaque Thickening at Baseline: Score 3 (Severe)	Plaque Thickening at Baseline: Score 4 (Very Severe)	Plaque Thickening at Week 2-LOCF: Score 0 (None)	Plaque Thickening at Week 2-LOCF: Score 1 (Mild)	Plaque Thickening at Week 2-LOCF: Score 2 (Moderate)	Plaque Thickening at Week 2-LOCF: Score 3 (Severe)	Plaque Thickening at Week 2- LOCF: Score 4 (Very Severe)	Plaque Thickening at Week 4- LOCF: Score 0 (None)	Plaque Thickening at Week 4- LOCF: Score 1 (Mild)	Plaque Thickening at Week 4-LOCF: Score 2 (Moderate)	Plaque Thickening at Week 4- LOCF: Score 3 (Severe)	Plaque Thickening at Week 4- LOCF: Score 4 (Very Severe)
Initial Phase:- Clobex® Shampoo	0	1.7	47.2	45.5	5.6	2.4	39.6	44.1	13.2	0.4	12.2	51.4	30.9	4.9	0.7	0	0.7	42.0	49.7	7.6	5.9	35.1	45.5	10.8	2.8	14.2	50.7	30.6	3.5	1.0	0.7	4.9	54.2	36.5	3.8	10.8	37.5	43.4	6.9	1.4	23.6	49.3	23.3	2.8	1.0

Intervention	percentage of participants (Number)
	Baseline: Score 0 (None)	Baseline: Score 1 (Mild)	Baseline: Score 2 (Moderate)	Baseline: Score 3 (Severe)	Week 2- LOCF: Score 0 (None)	Week 2- LOCF: Score 1 (Mild)	Week 2- LOCF: Score 2 (Moderate)	Week 2- LOCF: Score 3 (Severe)	Week 4- LOCF: Score 0 (None)	Week 4- LOCF: Score 1 (Mild)	Week 4- LOCF: Score 2 (Moderate)	Week 4- LOCF: Score 3 (Severe)
Initial Phase:- Clobex® Shampoo	3.8	20.8	51.7	23.6	19.8	53.5	23.6	3.1	35.4	47.6	15.6	1.4

Intervention	percentage of participants (Number)
	Maintenance Baseline : Relapse	Week 4 : Relapse	Week 8 : Relapse	Week 12 : Relapse	Week 16 : Relapse	Week 20 : Relapse	Week 24 : Relapse
Maintenance Phase: Clobex® Shampoo	0	41	52.8	55.7	62.9	66.7	68.9
Maintenance Phase: Clobex® Vehicle Shampoo	0	64.5	76.6	84.5	89.2	90.1	91.9

Intervention	percentage of participants (Number)
	Erythema: Score 0 (None)	Erythema: Score 1 (Mild)	Erythema: Score 2 (Moderate)	Erythema: Score 3 (Severe)	Erythema: Score 4 (Very Severe)	Scaling: Score 1 (Mild)	Scaling: Score 2 (Moderate)	Scaling: Score 3 (Severe)	Scaling: Score 4 (Very Severe)	Plaque Thickening: Score 0 (None)	Plaque Thickening: Score 1 (Mild)	Plaque Thickening: Score 2 (Moderate)	Plaque Thickening : Score 3 (Severe)	Plaque Thickening: Score 4 (Very Severe)
Maintenance Phase: Clobex® Shampoo	1.5	13.2	57.4	25.0	2.9	4.4	57.4	35.3	2.9	1.5	17.6	64.7	16.2	0
Maintenance Phase: Clobex® Vehicle Shampoo	0	13.4	54.6	30.9	1	4.1	64.9	29.9	1.0	2.1	14.4	67.0	14.4	2.1

Intervention	percentage of participants (Number)
	0: Zero Relapse	1: One Relapse	2: Two Relapse	3: Three Relapse	4: Two Consecutive Relapses
Clobex® Shampoo	31.1	26.4	9.4	7.5	25.5
Clobex® Vehicle Shampoo	8.1	22.5	25.2	18.0	26.1

Intervention	percentage of participants (Number)
	0: None	1: Mild	2: Moderate	3: Severe
Maintenance Phase: Clobex® Shampoo	13.2	29.4	51.5	5.9
Maintenance Phase: Clobex® Vehicle Shampoo	7.2	26.8	52.6	13.4

Intervention	participants (Number)
	Clear	Almost Clear	Mild	Moderate	Severe/Very Severe
Week 12	24	45	61	39	1
Week 2	22	69	54	24	1
Week 4	46	78	36	9	1
Week 8	35	50	68	17	0

Intervention	participants (Number)
	-1:Symptoms	0:No Change	1:Minimal Improvement	2:Definite Improvement	3:Considerable Improvement	4:Clearing
Week 12	0	13	19	49	58	31
Week 2	1	4	9	53	93	11
Week 4	0	2	4	26	96	42
Week 8	0	10	12	43	77	28

Intervention	participants (Number)
	None	Mild	Moderate	Severe
Baseline	303	1	0	1
Week 12	230	5	0	0
Week 2	284	4	0	0
Week 4	283	2	0	0
Week 8	273	1	0	0

Intervention	participants (Number)
	Absent	Present
Baseline	303	2
Week 12	233	2
Week 2	286	2
Week 4	278	7
Week 8	270	4

Intervention	Participants (Number)
Clobetasol Propionate Spray	48
Clobetasol Propionate Ointment	52

Intervention	% BSA (Mean)
Clobetasol Propionate Spray	28.6
Clobetasol Propionate Ointment	35.9

Intervention	% BSA (Mean)
Clobetasol Propionate Spray	48
Clobetasol Propionate Ointment	37.6

Intervention	% BSA (Mean)
Clobetasol Propionate Spray	29.1
Clobetasol Propionate Ointment	38.4

Intervention	% BSA (Mean)
Clobetasol Propionate Spray	48.6
Clobetasol Propionate Ointment	38.3

Intervention	Mean Percent Improvement (Mean)
	Percent improvement of PGA score at Week 2	Percent improvement of PGA score at Week 6	Percent improvement of PGA score at Week 12	Percent improvement of OTLS score at Week 2	Percent improvement of OTLS score at Week 6	Percent improvement of OTLS score at Week 12
Corticosteroid + LCD	39	47	31	43	46	29
Corticosteroid + Placebo	34	25	12	43	20	7

Intervention	percentage of participants (Number)
	Percentage with PGA scores ≤ 1 at Week 2	Percentage with PGA scores ≤ 1 at Week 6	Percentage with PGA scores ≤ 1 at Week 12
Corticosteroid + LCD	33.3	46.2	25.0
Corticosteroid + Placebo	6.7	15.4	16.7

Intervention	participants (Number)
	Baseline (Week 0), n=28, 30	Week 4, n=27, 28
Olux-E Foam	0	6
Vehicle Foam	0	4

Intervention	participants (Number)
	Week 1, n=26, 30	Week 2, n=26, 30	Week 4, n=27, 28
Olux-E Foam	6	19	12
Vehicle Foam	2	3	2

clobetasol

Description

Cross-References

Synonyms (50)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (8)

Protein Targets (6)

Potency Measurements

Bioassays (41)

Research

Studies (1,421)

Market Indicators

Research Demand Index: 117.16

Study Types

Clinical Trials (109)

Trial Overview

Trial Outcomes

Maintenance Phase: Time to First Relapse

Initial Phase: Percentage of Participants With Global Severity Scores

Initial Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores

Initial Phase: Percentage of Participants With Pruritus Scores

Maintenance Phase: Percentage of Participants Who Had First Relapse

Maintenance Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores at First Time of Relapse

Maintenance Phase: Percentage of Participants With Number of Relapses Experienced

Maintenance Phase: Percentage of Participants With Scalp Psoriasis Pruritus Score at First Time of Relapse

Number of Subjects With Improvement in Lesional Psoriasis Area and Assessment (PASI) Score After Imiquimod and UVB Treatment

Number of Subjects With Elevated MyxA

Number of Subjects With a 1.5 Fold Increase in mRNA Expression of GRAMD1A and DMXL2

Signs of Psoriasis - Plaque Elevation

Signs of Psoriasis - Erythema

Overall Disease Severity

Global Improvement Score

Percent Change From Baseline in Body Surface Area (% BSA) Affected

Tolerability Assessment - Telangiectasias

Tolerability Assessment - Stinging/ Burning

Overall Disease Severity Success (ODS)

Tolerability Assessment - Skin Atrophy

Tolerability Assessment - Pruritus

Tolerability Assessment - Folliculitis

Signs of Psoriasis - Scaling

Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to After Two Weeks of Treatment

Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to After Two Weeks of Treatment

Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to End of Treatment

Percent Decrease in Body Surface Area Affected (%BSA Affected) From Baseline to Two Weeks Post Treatment

Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to After Two Weeks of Treatment

Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to End of Treatment

Percent Decrease in Body Surface Area Treated (%BSA Treated) From Baseline to Two Weeks Post Treatment

Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to End of Treatment

Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to 2 Weeks Post Treatment Based on the Overall Disease Severity (ODS) Scale

Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to After Two Weeks of Treatment Based on the Overall Disease Severity (ODS) Scale

Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale

Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to After Two Weeks of Treatment

Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to End of Treatment

Number of Participants With Decrease in Signs of Psoriasis (Erythema) From Baseline to Two Weeks Post Treatment

Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) From Baseline to Two Weeks Post Treatment

Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to After Two Weeks of Treatment

Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to End of Treatment

Number of Participants With Decrease in Signs of Psoriasis (Scaling) From Baseline to Two Weeks Post Treatment

Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Weeks Post Treatment

Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions

Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit.

Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips

Change in Subject's Visual Analogue Assessment Scale

Change in Subject's Visual Analogue Assessment Scale From Baseline to Day 15

Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers

Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands

Proportion of Subjects With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Fingers

Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands

Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score

Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.

Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists

Intervention	participants (Number)
	Day 3 Score 0 -1 No effect	Day 3 Score 2- 5 Small effect	Day 3 Score 6- 10 Moderate effect	Day 3 Score 11- 20 Very large effect	Day 8 Score 0 -1 No effect	Day 8 Score 2- 5 Small effect	Day 8 Score 6- 10 Moderate effect	Day 8 Score 11- 20 Very large effect	Day 15 Score 0 -1 No effect	Day 15 Score 2- 5 Small effect	Day 15 Score 6- 10 Moderate effect	Day 15 Score 11- 20 Very large effect
Clobex Lotion	4	4	7	2	7	6	3	1	10	5	1	1
Olux-E Foam	5	6	5	0	9	4	3	1	11	3	2	1

Intervention	units on a scale (Mean)
	Day 3, n=16, 17	Day 8, n=17, 17	Day 15, n=17, 17
Clobex Lotion	1.41	0.88	0.82
Olux-E Foam	0.56	0.53	0.53

Intervention	units on a scale (Mean)
	Day 3, n=15, 17	Day 8, n=16, 17	Day 15, n=17, 17
Clobex Lotion	0.41	0.29	0.12
Olux-E Foam	0.33	0.25	0.18

Intervention	units on a scale (Mean)
	Day 3	Day 8	Day 15
Clobex Lotion	5.76	3.29	2.41
Olux-E Foam	3.75	2.65	2.12

Intervention	Percent change (Median)
C Propionate 4/Week + Ketoconazole 2/Week	-71.4
C Propionate 2/Week + Ketoconazole 2/Week	-66.7
C Propionate 2/Week	-66.7
Ketakonazol 2/Week	-57.1

Intervention	participants (Number)
	Scaling Baseline None (0)	Scaling Week 4 None (0)	Scaling Baseline Mild (1)	Scaling Week 4 Mild (1)	Scaling Baseline Moderate (2)	Scaling Week 4 Moderate (2)	Scaling Baseline Severe (3)	Scaling Week 4 Severe (3)	Scaling Baseline Very Severe (4)	Scaling Week 4 Very Severe (4)	Erythema Baseline None (0)	Erythema Week 4 None (0)	Erythema Baseline Mild (1)	Erythema Week 4 Mild (1)	Erythema Baseline Moderate (2)	Erythema Week 4 Moderate (2)	Erythema Baseline Severe (3)	Erythema Week 4 Severe (3)	Erythema Baseline Very Severe (4)	Erythema Week 4 Very Severe (4)	Plaque Elevation Baseline None (0)	Plaque Elevation Week 4 None (0)	Plaque Elevation Baseline Mild (1)	Plaque Elevation Week 4 Mild (1)	Plaque Elevation Baseline Moderate (2)	Plaque Elevation Week 4 Moderate (2)	Plaque Elevation Baseline Severe (3)	Plaque Elevation Week 4 Severe (3)	Plaque Elevation Baseline Very Severe (4)	Plaque Elevation Week 4 Very Severe (4)
Clobex Spray	0	24	4	15	22	1	12	1	3	0	0	24	3	14	30	3	8	0	0	0	0	26	7	13	19	1	13	1	2	0
Vehicle Spray	0	3	2	9	26	21	11	7	1	0	1	3	4	11	26	20	9	6	0	0	0	7	2	12	27	19	11	2	0	0

Intervention	participants (Number)
	Extent of Scalp Involvement Baseline None	Extent of Scalp Involvement Week 4 None	Extent of Scalp Involvement Baseline <20%	Extent of Scalp Involvement Week 4 <20%	Extent of Scalp Involvement Baseline 20-39%	Extent of Scalp Involvement Week 4 20-39%	Extent of Scalp Involvement Baseline 40-59%	Extent of Scalp Involvement Week 4 40-59%	Extent of Scalp Involvement Baseline 60-79%	Extent of Scalp Involvement Week 4 60-79%	Extent of Scalp Involvement Baseline 80-100%	Extent of Scalp Involvement Week 4 80-100%
Clobex Spray	0	21	16	16	5	4	12	0	6	0	2	0
Vehicle Spray	0	1	12	16	6	12	14	4	5	5	3	2

Intervention	participants (Number)
	Pruritus Baseline None (0)	Pruritus Week 4 None (0)	Pruritus Baseline Mild (1)	Pruritus Week 4 Mild (1)	Pruritus Baseline Moderate (2)	Pruritus Week 4 Moderate (2)	Pruritus Baseline Severe (3)	Pruritus Week 4 Severe (3)
Clobex Spray	4	28	5	12	29	1	3	0
Vehicle Spray	1	8	10	14	24	14	5	4

Intervention	Percent change (Median)
Vectical® Ointment (Weekdays) and Clobex® Spray (Weekends)	-33.3
Clobex® Spray (Morning) and Vectical® Ointment (Evening)	-50.0

Intervention	participants (Number)
	Strongly agree	Moderately agree	No opinion	Moderately disagree	Strongly disagree	Missing
Clobex® Spray (Morning) and Vectical® Ointment (Evening)	25	32	4	5	1	1
Vectical® Ointment (Weekdays) and Clobex® Spray (Weekends)	10	39	6	9	3	3